In-practice Evaluation of Atacand 16mg Antihypertensive Effect
Study identifier:NIS-CLV-ATA-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
Medical condition
essential hypertension
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
400
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Nov 2008
Primary Completion Date: 01 Jan 2009
Study Completion Date: 01 Jan 2009
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC. | - |
Contacts
Investigators
Principal Investigator
Agrita Hartmane
AstraZeneca
